"Vincristine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
| Descriptor ID |
D014750
|
| MeSH Number(s) |
D03.132.436.681.827.817 D03.633.100.473.402.681.827.817
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Vincristine".
Below are MeSH descriptors whose meaning is more specific than "Vincristine".
This graph shows the total number of publications written about "Vincristine" by people in this website by year, and whether "Vincristine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 2 | 2 |
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 2 | 2 |
| 2003 | 1 | 0 | 1 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 3 | 3 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 6 | 6 |
| 2009 | 0 | 2 | 2 |
| 2010 | 1 | 3 | 4 |
| 2011 | 0 | 7 | 7 |
| 2012 | 0 | 3 | 3 |
| 2013 | 1 | 5 | 6 |
| 2014 | 1 | 2 | 3 |
| 2015 | 2 | 4 | 6 |
| 2016 | 0 | 4 | 4 |
| 2017 | 1 | 3 | 4 |
| 2018 | 0 | 7 | 7 |
| 2019 | 1 | 7 | 8 |
| 2020 | 3 | 5 | 8 |
| 2021 | 1 | 5 | 6 |
| 2022 | 0 | 5 | 5 |
| 2023 | 0 | 2 | 2 |
| 2024 | 1 | 4 | 5 |
| 2025 | 1 | 3 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vincristine" by people in Profiles.
-
Dinaciclib improves treatment response in chemoresistant hepatoblastoma. Sci Rep. 2025 Dec 05; 16(1):1410.
-
Feasibility of Atezolizumab in Combination With Chemotherapy for Children With Relapsed or Refractory Solid Tumors. Pediatr Blood Cancer. 2025 Dec; 72(12):e32046.
-
Hematology-oncology provider perspectives regarding lymphoma treatment and cardioprotective strategies in patients with lymphoma at high risk for heart failure. Leuk Lymphoma. 2025 Aug; 66(8):1437-1446.
-
Vincristine Sulfate Liposome Injection With Combination Chemotherapy for Children, Adolescents, and Young Adults With Relapsed Acute Lymphoblastic Leukemia: A Therapeutic Advances in Childhood Leukemia and Lymphoma Consortium Trial. Pediatr Blood Cancer. 2025 May; 72(5):e31584.
-
Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group. Lancet Oncol. 2024 07; 25(7):912-921.
-
Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024 08; 99(8):1586-1594.
-
Treatment patterns, clinical outcomes and gene mutation characteristics of hepatitis B virus-associated mantle cell lymphoma. Hematol Oncol. 2024 May; 42(3):e3268.
-
A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen. Blood Adv. 2024 04 09; 8(7):1612-1620.
-
A novel treatment strategy utilizing panobinostat for high-risk and treatment-refractory hepatoblastoma. J Hepatol. 2024 04; 80(4):610-621.
-
Treatment outcomes of extraskeletal Ewing sarcoma. J Surg Oncol. 2023 Jul; 128(1):105-110.